Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, one haplotype in each DRD2 haploblocks was associated with a 29 to 50% increase in dyskinesia risk.
|
29191473 |
2018 |
Dyskinetic syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
|
29525397 |
2018 |
Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From 37 candidate studies on levodopa toxicity, 18 genes were found associated, of which, CA<sub>n</sub> STR 13, 14 (DRD2) was most significantly associated with dyskinesia, followed by rs1801133 (MTHFR) with hyper-homocysteinemia, and rs474559 (HOMER1) with hallucination.
|
28927418 |
2017 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
|
28583881 |
2017 |
Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
|
24633632 |
2014 |
Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor fluctuations in Parkinson's disease patients.
|
23171335 |
2012 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pathogenesis of dyskinesia may result from divergent changes in dopamine D1 receptors (DRD1) and dopamine D2 receptors (DRD2) in the brain while aging.
|
21181138 |
2011 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
LHGDN |
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.
|
17767146 |
2007 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
LHGDN |
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.
|
16959057 |
2007 |
Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia.
|
17669630 |
2007 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
|
16435402 |
2006 |
Dyskinetic syndrome
|
0.400 |
Biomarker
|
disease |
LHGDN |
The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia.
|
16769201 |
2006 |
Dyskinetic syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Certain alleles of the short tandem repeat polymorphism of the dopamine receptor D2 gene reduce the risk of developing peak-dose dyskinesias and could contribute to varying susceptibility to develop peak-dose dyskinesias during levodopa therapy.
|
10534246 |
1999 |